Levon M Khachigian

List of Publications by Citations

183 papers	9,527 citations	52 h-index	92 g-index
214 ext. papers	10,722 ext. citations	8.4 avg, IF	6.16 L-index

#	Paper	IF	Citations
183	A promoter-level mammalian expression atlas. *Nature*, **2014**, 507, 462-70	50.4	1301
182	Transcribed enhancers lead waves of coordinated transcription in transitioning mammalian cells. *Science*, **2015**, 347, 1010-4	33.3	384
181	Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth. *Nature Medicine*, **2003**, 9, 1026-32	50.5	294
180	Coronary in-stent restenosis: current status and future strategies. *Journal of the American College of Cardiology*, **2002**, 39, 183-93	15.1	279
179	Sp1 phosphorylation and its regulation of gene transcription. *Molecular and Cellular Biology*, **2009**, 29, 2483-8	4.8	246
178	Interplay of Sp1 and Egr-1 in the proximal platelet-derived growth factor A-chain promoter in cultured vascular endothelial cells. *Journal of Biological Chemistry*, **1995**, 270, 27679-86	5.4	244
177	Early growth response-1 in cardiovascular pathobiology. *Circulation Research*, **2006**, 98, 186-91	15.7	224
176	New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury. *Nature Medicine*, **1999**, 5, 1264-9	50.5	213
175	Egr-1 is activated in endothelial cells exposed to fluid shear stress and interacts with a novel shear-stress-response element in the PDGF A-chain promoter. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1997**, 17, 2280-6	9.4	165
174	Galectin-1 interacts with the {alpha}5{beta}1 fibronectin receptor to restrict carcinoma cell growth via induction of p21 and p27. *Journal of Biological Chemistry*, **2005**, 280, 37266-77	5.4	137
173	Dominantly inherited constitutional epigenetic silencing of MLH1 in a cancer-affected family is linked to a single nucleotide variant within the 5′UTR. *Cancer Cell*, **2011**, 20, 200-13	24.3	136
172	Effect of deoxyribozymes targeting c-Jun on solid tumor growth and angiogenesis in rodents. *Journal of the National Cancer Institute*, **2004**, 96, 683-96	9.7	136
171	Inducible expression of Egr-1-dependent genes. A paradigm of transcriptional activation in vascular endothelium. *Circulation Research*, **1997**, 81, 457-61	15.7	120
170	DNAzyme technology and cancer therapy: cleave and let die. *Molecular Cancer Therapeutics*, **2008**, 7, 243-51	6.1	117
169	Collagen antibody-induced arthritis. *Nature Protocols*, **2006**, 1, 2512-6	18.8	109
168	Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies. *American Journal of Pathology*, **2007**, 171, 1079-88	5.8	105
167	Early growth response factor-1 induction by injury is triggered by release and paracrine activation by fibroblast growth factor-2. *American Journal of Pathology*, **1999**, 154, 937-44	5.8	105

166	Sp1 is a component of the cytokine-inducible enhancer in the promoter of vascular cell adhesion molecule-1. *Journal of Biological Chemistry*, **1995**, 270, 28903-9	5.4	103
165	Protein-protein interaction between Fli-1 and GATA-1 mediates synergistic expression of megakaryocyte-specific genes through cooperative DNA binding. *Molecular and Cellular Biology*, **2003**, 23, 3427-41	4.8	101
164	Catalytic oligodeoxynucleotides define a key regulatory role for early growth response factor-1 in the porcine model of coronary in-stent restenosis. *Circulation Research*, **2001**, 89, 670-7	15.7	100
163	Inhibition of human breast carcinoma proliferation, migration, chemoinvasion and solid tumour growth by DNAzymes targeting the zinc finger transcription factor EGR-1. *Nucleic Acids Research*, **2004**, 32, 3065-9	20.1	97
162	Suppression of vascular permeability and inflammation by targeting of the transcription factor c-Jun. *Nature Biotechnology*, **2006**, 24, 856-63	44.5	94
161	Isolation and characterization of a novel zinc-finger protein with transcription repressor activity. *Journal of Biological Chemistry*, **1995**, 270, 22143-52	5.4	94
160	ERK, JNK, and p38 MAP kinases differentially regulate proliferation and migration of phenotypically distinct smooth muscle cell subtypes. *Journal of Cellular Biochemistry*, **2003**, 89, 289-300	4.7	93
159	Hemodynamics, endothelial gene expression, and atherogenesis. *Annals of the New York Academy of Sciences*, **1997**, 811, 1-10; discussion 10-1	6.5	92
158	FANTOM5 CAGE profiles of human and mouse samples. *Scientific Data*, **2017**, 4, 170112	8.2	88
157	Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma. *Journal of the National Cancer Institute*, **2003**, 95, 1394-403	9.7	86
156	c-Jun regulates vascular smooth muscle cell growth and neointima formation after arterial injury. Inhibition by a novel DNA enzyme targeting c-Jun. *Journal of Biological Chemistry*, **2002**, 277, 22985-91	5.4	86
155	Endothelial gene regulation by laminar shear stress. *Advances in Experimental Medicine and Biology*, **1997**, 430, 155-64	3.6	85
154	Induction of platelet-derived growth factor B-chain expression by transforming growth factor-beta involves transactivation by Smads. *Journal of Biological Chemistry*, **2000**, 275, 16709-16	5.4	83
153	Macrophage migration inhibitory factor increases leukocyte-endothelial interactions in human endothelial cells via promotion of expression of adhesion molecules. *Journal of Immunology*, **2010**, 185, 1238-47	5.3	80
152	The role of platelet □granular proteins in the regulation of thrombopoietin messenger RNA expression in human bone marrow stromal cells. *Blood*, **2000**, 95, 3094-3101	2.2	79
151	c-Jun regulates shear- and injury-inducible Egr-1 expression, vein graft stenosis after autologous end-to-side transplantation in rabbits, and intimal hyperplasia in human saphenous veins.. *Journal of Biological Chemistry*, **2013**, 288, 31918	5.4	78
150	Protein-Protein Interaction between Fli-1 and GATA-1 Mediates Synergistic Expression of Megakaryocyte-Specific Genes through Cooperative DNA Binding. *Molecular and Cellular Biology*, **2004**, 24, 5088-5088	4.8	78
149	TRAIL stimulates proliferation of vascular smooth muscle cells via activation of NF-kappaB and induction of insulin-like growth factor-1 receptor. *Journal of Biological Chemistry*, **2008**, 283, 7754-62	5.4	73

148	Current and potential treatments for cervical cancer. *Current Cancer Drug Targets*, **2013**, 13, 205-20	2.8	71
147	Safety and tolerability of an intratumorally injected DNAzyme, Dz13, in patients with nodular basal-cell carcinoma: a phase 1 first-in-human trial (DISCOVER). *Lancet, The*, **2013**, 381, 1835-43	40	69
146	The Yin and Yang of YY1 in tumor growth and suppression. *International Journal of Cancer*, **2018**, 143, 460-465	7.5	67
145	Early growth response gene 1 (EGR1) regulates heparanase gene transcription in tumor cells. *Journal of Biological Chemistry*, **2005**, 280, 35136-47	5.4	67
144	Fibroblast growth factor-2 represses platelet-derived growth factor receptor-alpha (PDGFR-alpha) transcription via ERK1/2-dependent Sp1 phosphorylation and an atypical cis-acting element in the proximal PDGFR-alpha promoter. *Journal of Biological Chemistry*, **2004**, 279, 2377-82	5.4	66
143	TRAIL promotes VSMC proliferation and neointima formation in a FGF-2-, Sp1 phosphorylation-, and NFkappaB-dependent manner. *Circulation Research*, **2010**, 106, 1061-71	15.7	64
142	Sp1 inhibits proliferation and induces apoptosis in vascular smooth muscle cells by repressing p21WAF1/Cip1 transcription and cyclin D1-Cdk4-p21WAF1/Cip1 complex formation. *Journal of Biological Chemistry*, **2003**, 278, 32537-43	5.4	64
141	Regulation of inducible heparanase gene transcription in activated T cells by early growth response 1. *Journal of Biological Chemistry*, **2003**, 278, 50377-85	5.4	64
140	Early growth response-1 regulates angiopoietin-1-induced endothelial cell proliferation, migration, and differentiation. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2009**, 29, 209-16	9.4	63
139	Sp1 phosphorylation regulates apoptosis via extracellular FasL-Fas engagement. *Journal of Biological Chemistry*, **2001**, 276, 4964-71	5.4	63
138	Yin Yang-1 inhibits vascular smooth muscle cell growth and intimal thickening by repressing p21WAF1/Cip1 transcription and p21WAF1/Cip1-Cdk4-cyclin D1 assembly. *Circulation Research*, **2007**, 101, 146-55	15.7	56
137	Phosphomannopentaose sulfate (PI-88): heparan sulfate mimetic with clinical potential in multiple vascular pathologies. *Cardiovascular Drug Reviews*, **2004**, 22, 1-6		56
136	Sp1 phosphorylation regulates inducible expression of platelet-derived growth factor B-chain gene via atypical protein kinase C-zeta. *Nucleic Acids Research*, **2001**, 29, 1027-33	20.1	55
135	Ets-1 positively regulates Fas ligand transcription via cooperative interactions with Sp1. *Journal of Biological Chemistry*, **2002**, 277, 36244-52	5.4	55
134	Vascular smooth muscle cell proliferation and regrowth after mechanical injury in vitro are Egr-1/NGFI-A-dependent. *American Journal of Pathology*, **1999**, 155, 897-905	5.8	54
133	Regulation of PDGF-B in endothelial cells exposed to cyclic strain. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1998**, 18, 349-55	9.4	52
132	GILZ overexpression inhibits endothelial cell adhesive function through regulation of NF-B and MAPK activity. *Journal of Immunology*, **2013**, 191, 424-33	5.3	50
131	Blockade of vascular smooth muscle cell proliferation and intimal thickening after balloon injury by the sulfated oligosaccharide PI-88: phosphomannopentaose sulfate directly binds FGF-2, blocks cellular signaling, and inhibits proliferation. *Circulation Research*, **2003**, 92, e70-7	15.7	50

130	GC factor 2 represses platelet-derived growth factor A-chain gene transcription and is itself induced by arterial injury. *Circulation Research*, **1999**, 84, 1258-67	15.7	50
129	Modulation of growth factor gene expression in vascular cells by oxidative stress. *Endothelium: Journal of Endothelial Cell Research*, **2004**, 11, 133-9		49
128	Regulation of vascular leak and recovery from ischemic injury by general and VE-cadherin-restricted miRNA antagonists of miR-27. *Blood*, **2013**, 122, 2911-9	2.2	48
127	PDGF beta-receptor kinase activity and ERK1/2 mediate glycosaminoglycan elongation on biglycan and increases binding to LDL. *Endocrinology*, **2010**, 151, 4356-67	4.8	47
126	Catalytic DNAs as potential therapeutic agents and sequence-specific molecular tools to dissect biological function. *Journal of Clinical Investigation*, **2000**, 106, 1189-95	15.9	47
125	Crucial role for early growth response-1 in the transcriptional regulation of miR-20b in breast cancer. *Oncotarget*, **2013**, 4, 1373-87	3.3	47
124	Albendazole inhibits endothelial cell migration, tube formation, vasopermeability, VEGF receptor-2 expression and suppresses retinal neovascularization in ROP model of angiogenesis. *Biochemical and Biophysical Research Communications*, **2010**, 397, 729-34	3.4	46
123	Oxidative stress regulates IGF1R expression in vascular smooth-muscle cells via p53 and HDAC recruitment. *Biochemical Journal*, **2007**, 407, 79-87	3.8	46
122	Rat models of myocardial infarction. *Thrombosis and Haemostasis*, **2006**, 96, 602-610	7	46
121	DNAzyme targeting c-jun suppresses skin cancer growth. *Science Translational Medicine*, **2012**, 4, 139ra82	17.5	44
120	Zinc finger transcription factors mediate high constitutive platelet-derived growth factor-B expression in smooth muscle cells derived from aortae of newborn rats. *Journal of Biological Chemistry*, **1998**, 273, 5758-64	5.4	44
119	Vascular smooth muscle cells express the transcriptional corepressor NAB2 in response to injury. *American Journal of Pathology*, **1999**, 155, 1311-7	5.8	44
118	Fibroblast growth factor-2 induction of platelet-derived growth factor-C chain transcription in vascular smooth muscle cells is ERK-dependent but not JNK-dependent and mediated by Egr-1. *Journal of Biological Chemistry*, **2004**, 279, 40289-95	5.4	43
117	Catalytic Antisense DNA Molecules Targeting Egr-1 Inhibit Neointima Formation following Permanent Ligation of Rat Common Carotid Arteries. *Thrombosis and Haemostasis*, **2002**, 87, 134-140	7	43
116	Early growth response factor-1 mediates insulin-inducible vascular endothelial cell proliferation and regrowth after injury. *Journal of Cellular Biochemistry*, **2001**, 81, 523-34	4.7	43
115	FGF-1-induced platelet-derived growth factor-A chain gene expression in endothelial cells involves transcriptional activation by early growth response factor-1. *Circulation Research*, **1997**, 81, 282-8	15.7	43
114	Activation transcription factor-4 induced by fibroblast growth factor-2 regulates vascular endothelial growth factor-A transcription in vascular smooth muscle cells and mediates intimal thickening in rat arteries following balloon injury. *Circulation Research*, **2008**, 103, 378-87	15.7	42
113	Nucleic acid based strategies as potential therapeutic tools: mechanistic considerations and implications to restenosis. *Journal of Molecular Medicine*, **2001**, 79, 695-706	5.5	42

112	Angiotensin II (ATII)-inducible platelet-derived growth factor A-chain gene expression is p42/44 extracellular signal-regulated kinase-1/2 and Egr-1-dependent and mediated via the ATII type 1 but not type 2 receptor. Induction by ATII antagonized by nitric oxide. *Journal of Biological Chemistry*, **1999**, 274, 23726-33	5.4	42
111	Ets-1 stimulates platelet-derived growth factor A-chain gene transcription and vascular smooth muscle cell growth via cooperative interactions with Sp1. *Circulation Research*, **2004**, 95, 479-87	15.7	41
110	NF1/X represses PDGF A-chain transcription by interacting with Sp1 and antagonizing Sp1 occupancy of the promoter. *EMBO Journal*, **2002**, 21, 334-43	13	41
109	A key role for early growth response-1 and nuclear factor-kappaB in mediating and maintaining GRO/CXCR2 proliferative signaling in esophageal cancer. *Molecular Cancer Research*, **2009**, 7, 755-64	6.6	40
108	Ets-1 protects vascular smooth muscle cells from undergoing apoptosis by activating p21WAF1/Cip1: ETS-1 regulates basal and and inducible p21WAF1/Cip: ETS-1 regulates basal and inducible p21WAF1/Cip1 transcription via distinct cis-acting elements in the p21WAF/Cip1 promoter. *Journal of Biological Chemistry*, **2003**, 278, 27903-9	5.4	40
107	Locked nucleic acid modified DNA enzymes targeting early growth response-1 inhibit human vascular smooth muscle cell growth. *Nucleic Acids Research*, **2004**, 32, 2281-5	20.1	39
106	The cytoplasmic domain of tissue factor contributes to leukocyte recruitment and death in endotoxemia. *American Journal of Pathology*, **2004**, 165, 331-40	5.8	39
105	Induction of the transcriptional repressor Yin Yang-1 by vascular cell injury. Autocrine/paracrine role of endogenous fibroblast growth factor-2. *Journal of Biological Chemistry*, **2001**, 276, 41143-9	5.4	38
104	Sp1, acetylated histone-3 and p300 regulate TRAIL transcription: mechanisms of PDGF-BB-mediated VSMC proliferation and migration. *Journal of Cellular Biochemistry*, **2012**, 113, 2597-606	4.7	35
103	c-Jun DNAzymes inhibit myocardial inflammation, ROS generation, infarct size, and improve cardiac function after ischemia-reperfusion injury. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2009**, 29, 1836-42	9.4	33
102	Platelet-derived growth factor enhances platelet recovery in a murine model of radiation-induced thrombocytopenia and reduces apoptosis in megakaryocytes via its receptors and the PI3-k/Akt pathway. *Haematologica*, **2010**, 95, 1745-53	6.6	32
101	c-Jun knockdown sensitizes osteosarcoma to doxorubicin. *Molecular Cancer Therapeutics*, **2008**, 7, 1909-12	6.1	32
100	Phosphorylation and acetylation of histone H3 and autoregulation by early growth response 1 mediate interleukin 1beta induction of early growth response 1 transcription. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2010**, 30, 536-45	9.4	31
99	Regulatory roles of c-jun in H5N1 influenza virus replication and host inflammation. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2014**, 1842, 2479-88	6.9	29
98	Interplay between heme oxygenase-1 and the multifunctional transcription factor yin yang 1 in the inhibition of intimal hyperplasia. *Circulation Research*, **2010**, 107, 1490-7	15.7	29
97	Inducible platelet-derived growth factor D-chain expression by angiotensin II and hydrogen peroxide involves transcriptional regulation by Ets-1 and Sp1. *Blood*, **2006**, 107, 2322-9	2.2	29
96	Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review. *Oncotarget*, **2018**, 9, 21613-21627	3.3	29
95	Angiotensin II-inducible smooth muscle cell apoptosis involves the angiotensin II type 2 receptor, GATA-6 activation, and FasL-Fas engagement. *Circulation Research*, **2009**, 105, 422-30	15.7	28

94	Biocompatible chitosan-DNAzyme nanoparticle exhibits enhanced biological activity. *Journal of Microencapsulation*, **2008**, 25, 421-5	3.4	27
93	Angiotensin II-inducible platelet-derived growth factor-D transcription requires specific Ser/Thr residues in the second zinc finger region of Sp1. *Circulation Research*, **2008**, 102, e38-51	15.7	27
92	Suppression of growth factor expression and human vascular smooth muscle cell growth by small interfering RNA targeting EGR-1. *Journal of Cellular Biochemistry*, **2007**, 100, 1526-35	4.7	27
91	c-Jun Is critical for the progression of osteosarcoma: proof in an orthotopic spontaneously metastasizing model. *Molecular Cancer Research*, **2008**, 6, 1289-92	6.6	26
90	Downregulation of c-jun results in apoptosis-mediated anti-osteosarcoma activity in an orthotopic model. *Cancer Biology and Therapy*, **2008**, 7, 1033-6	4.6	26
89	Antisense Egr-1 RNA driven by the CMV promoter is an inhibitor of vascular smooth muscle cell proliferation and regrowth after injury. *Journal of Cellular Biochemistry*, **2002**, 84, 575-582	4.7	26
88	Circulating mediators of remote ischemic preconditioning: search for the missing link between non-lethal ischemia and cardioprotection. *Oncotarget*, **2019**, 10, 216-244	3.3	26
87	Drug-induced immune thrombocytopenia. *Hematology/Oncology Clinics of North America*, **2013**, 27, 521-40	3.1	24
86	Involvement of c-jun in human liposarcoma growth: supporting data from clinical immunohistochemistry and DNAzyme efficacy. *Cancer Biology and Therapy*, **2008**, 7, 1297-301	4.6	23
85	JUN siRNA regulates matrix metalloproteinase-2 expression, microvascular endothelial growth and retinal neovascularisation. *Journal of Cell Science*, **2006**, 119, 3219-26	5.3	23
84	Emerging therapeutic approaches in the management of retinal angiogenesis and edema. *Journal of Molecular Medicine*, **2011**, 89, 343-61	5.5	22
83	Peroxide-inducible Ets-1 mediates platelet-derived growth factor receptor-alpha gene transcription in vascular smooth muscle cells. *American Journal of Pathology*, **2005**, 167, 1149-59	5.8	22
82	Deoxyribozymes as Catalytic Nanotherapeutic Agents. *Cancer Research*, **2019**, 79, 879-888	10.1	22
81	Early growth response-1 in the pathogenesis of cardiovascular disease. *Journal of Molecular Medicine*, **2016**, 94, 747-53	5.5	21
80	Selective inhibition of the master regulator transcription factor Egr-1 with catalytic oligonucleotides reduces myocardial injury and improves left ventricular systolic function in a preclinical model of myocardial infarction. *Journal of the American Heart Association*, **2013**, 2, e000023	6	21
79	Nuclear import of early growth response-1 involves importin-7 and the novel nuclear localization signal serine-proline-serine. *International Journal of Biochemistry and Cell Biology*, **2011**, 43, 905-12	5.6	21
78	c-Jun regulates shear- and injury-inducible Egr-1 expression, vein graft stenosis after autologous end-to-side transplantation in rabbits, and intimal hyperplasia in human saphenous veins. *Journal of Biological Chemistry*, **2010**, 285, 4038-4048	5.4	21
77	Intracoronary delivery of DNAzymes targeting human EGR-1 reduces infarct size following myocardial ischaemia reperfusion. *Journal of Pathology*, **2012**, 227, 157-64	9.4	20

76	DNAzymes: cutting a path to a new class of therapeutics. *Current Opinion in Molecular Therapeutics*, **2002**, 4, 119-21		19
75	The anthelmintic flubendazole blocks human melanoma growth and metastasis and suppresses programmed cell death protein-1 and myeloid-derived suppressor cell accumulation. *Cancer Letters*, **2019**, 459, 268-276	9.9	18
74	Angiotensin II induction of PDGF-C expression is mediated by AT1 receptor-dependent Egr-1 transactivation. *Nucleic Acids Research*, **2008**, 36, 1941-51	20.1	18
73	Platelet-derived growth factor and alternative splicing: a review. *Pathology*, **1992**, 24, 280-90	1.6	18
72	Early Growth Response-1: Blocking Angiogenesis by Shooting the Messenger. *Cell Cycle*, **2004**, 3, 9-10	4.7	17
71	Neutralizing the pathological effects of extracellular histones with small polyanions. *Nature Communications*, **2020**, 11, 6408	17.4	17
70	Drug-induced thrombocytopenia: development of a novel NOD/SCID mouse model to evaluate clearance of circulating platelets by drug-dependent antibodies and the efficacy of IVIG. *Blood*, **2010**, 116, 1958-60	2.2	16
69	Transcriptional dynamics reveal critical roles for non-coding RNAs in the immediate-early response. *PLoS Computational Biology*, **2015**, 11, e1004217	5	15
68	Activation transcription factor-4 and the acute vascular response to injury. *Journal of Molecular Medicine*, **2010**, 88, 545-52	5.5	15
67	von Hippel-Lindau tumor suppressor protein represses platelet-derived growth factor B-chain gene expression via the Sp1 binding element in the proximal PDGF-B promoter. *Journal of Cellular Biochemistry*, **2002**, 85, 490-5	4.7	15
66	IL-1beta signals through the EGF receptor and activates Egr-1 through MMP-ADAM. *PLoS ONE*, **2012**, 7, e39811	3.7	15
65	Remote Ischemic Preconditioning induces Cardioprotective Autophagy and Signals through the IL-6-Dependent JAK-STAT Pathway. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	14
64	"Summer Shift": A Potential Effect of Sunshine on the Time Onset of ST-Elevation Acute Myocardial Infarction. *Journal of the American Heart Association*, **2018**, 7,	6	14
63	Extracellular matrix is a source of mitogenically active platelet-derived growth factor. *Journal of Cellular Physiology*, **1996**, 168, 322-32	7	14
62	Recruitment and maturation of the coronary collateral circulation: Current understanding and perspectives in arteriogenesis. *Microvascular Research*, **2020**, 132, 104058	3.7	14
61	Catalytic antisense DNA molecules targeting Egr-1 inhibit neointima formation following permanent ligation of rat common carotid arteries. *Thrombosis and Haemostasis*, **2002**, 87, 134-40	7	14
60	Genistein inhibits PDGF-stimulated proteoglycan synthesis in vascular smooth muscle without blocking PDGF receptor phosphorylation. *Archives of Biochemistry and Biophysics*, **2012**, 525, 25-31	4.1	13
59	Recent developments in drug-eluting stents. *Journal of Molecular Medicine*, **2011**, 89, 545-53	5.5	13

58	Vascular smooth muscle cell-specific regulation of cyclin-dependent kinase inhibitor p21(WAF1/Cip1) transcription by Sp1 is mediated via distinct cis-acting positive and negative regulatory elements in the proximal p21(WAF1/Cip1) promoter. *Journal of Cellular Biochemistry*, **2004**, 93, 904-16	4.7	13
57	Structural basis for the extracellular retention of PDGF A-chain using a synthetic peptide corresponding to exon 6. *Peptides*, **1994**, 15, 133-7	3.8	12
56	Comparative transcriptomics of primary cells in vertebrates. *Genome Research*, **2020**, 30, 951-961	9.7	12
55	MicroRNA miR-191 targets the zinc finger transcription factor Egr-1 and suppresses intimal thickening after carotid injury. *International Journal of Cardiology*, **2016**, 212, 299-302	3.2	12
54	DNAzyme delivery approaches in biological settings. *Current Medicinal Chemistry*, **2013**, 20, 3448-55	4.3	11
53	Yin Yang-1 inhibits tumor cell growth and inhibits p21WAF1/Cip1 complex formation with cdk4 and cyclin D1. *International Journal of Oncology*, **2012**, 40, 1575-80	4.4	11
52	Melanoma protective antitumor immunity activated by catalytic DNA. *Oncogene*, **2018**, 37, 5115-5126	9.2	11
51	Transcription Factors Targeted by miRNAs Regulating Smooth Muscle Cell Growth and Intimal Thickening after Vascular Injury. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	10
50	Platelet-derived growth factor-BB mediates cell migration through induction of activating transcription factor 4 and tenascin-C. *American Journal of Pathology*, **2012**, 180, 2590-7	5.8	10
49	SUMOylation regulates the transcriptional repression activity of FOG-2 and its association with GATA-4. *PLoS ONE*, **2012**, 7, e50637	3.7	10
48	The role of c-jun in PDTC-sensitive flow-dependent restenosis after angioplasty and stenting. *Atherosclerosis*, **2007**, 194, 364-71	3.1	10
47	Acute Local Release of Fibroblast Growth Factor-2 but not Transforming Growth Factor-β following Coronary Stenting. *Thrombosis and Haemostasis*, **2001**, 85, 574-576	7	10
46	Inhibition of vein graft stenosis with a c-jun targeting DNAzyme in a cationic liposomal formulation containing 1,2-dioleoyl-3-trimethylammonium propane (DOTAP)/1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE). *International Journal of Cardiology*, **2013**, 168, 3659-64	3.2	9
45	PDGF-D expression is down-regulated by TGFβ in fibroblasts. *PLoS ONE*, **2014**, 9, e108656	3.7	9
44	Mechanisms of angiotensin II-induced platelet-derived growth factor gene expression. *Molecular and Cellular Biochemistry*, **2000**, 212, 183-186	4.2	9
43	Antisense Egr-1 RNA driven by the CMV promoter is an inhibitor of vascular smooth muscle cell proliferation and regrowth after injury. *Journal of Cellular Biochemistry*, **2002**, 84, 575-82	4.7	9
42	Histone deacetylase-1 is enriched at the platelet-derived growth factor-D promoter in response to interleukin-1beta and forms a cytokine-inducible gene-silencing complex with NF-kappab p65 and interferon regulatory factor-1. *Journal of Biological Chemistry*, **2009**, 284, 35101-12	5.4	8
41	Injury-induced platelet-derived growth factor receptor-alpha expression mediated by interleukin-1beta (IL-1beta) release and cooperative transactivation by NF-kappaB and ATF-4: IL-1beta facilitates HDAC-1/2 dissociation from promoter. *Journal of Biological Chemistry*, **2009**, 284, 27933-27943	5.4	8

40	A crossreactive antipeptide monoclonal antibody with specificity for lysyl-lysine. *Journal of Immunological Methods*, **1991**, 140, 249-58	2.5	8
39	Inhibition of intimal thickening after vascular injury with a cocktail of vascular endothelial growth factor and cyclic Arg-Gly-Asp peptide. *International Journal of Cardiology*, **2016**, 220, 185-91	3.2	7
38	Reduced retinal microvascular density, improved forepaw reach, comparative microarray and gene set enrichment analysis with c-jun targeting DNA enzyme. *PLoS ONE*, **2012**, 7, e39160	3.7	7
37	Succinobucol induces apoptosis in vascular smooth muscle cells. *Free Radical Biology and Medicine*, **2012**, 52, 871-9	7.8	7
36	Repression of PDGF-R-□after cellular injury involves TNF-□formation of a c-Fos-YY1 complex, and negative regulation by HDAC. *American Journal of Physiology - Cell Physiology*, **2012**, 302, C1590-8	5.4	7
35	Fibroblast growth factor 2 and the transcription factor Egr-1 localise to endothelial cell microvascular channels in human coronary artery occlusion. *Thrombosis and Haemostasis*, **2005**, 93, 172-174	7	7
34	Early growth response-1: blocking angiogenesis by shooting the messenger. *Cell Cycle*, **2004**, 3, 10-1	4.7	7
33	Thermostable small-molecule inhibitor of angiogenesis and vascular permeability that suppresses a pERK-FosB/□osB-VCAM-1 axis. *Science Advances*, **2020**, 6, eaaz7815	14.3	6
32	Promoter Usage and Dynamics in Vascular Smooth Muscle Cells Exposed to Fibroblast Growth Factor-2 or Interleukin-1□*Scientific Reports*, **2018**, 8, 13164	4.9	6
31	Extracellular signal-regulated kinase-1 phosphorylates early growth response-1 at serine 26. *Biochemical and Biophysical Research Communications*, **2019**, 510, 345-351	3.4	5
30	Developing Neolignans as Proangiogenic Agents: Stereoselective Total Syntheses and Preliminary Biological Evaluations of the Four Guaiacylglycerol 8--4RConiferyl Ethers. *ACS Omega*, **2017**, 2, 7375-7388	3.9	5
29	Pharmaceutical patents: reconciling the human right to health with the incentive to invent. *Drug Discovery Today*, **2020**, 25, 1135-1141	8.8	4
28	Divergent roles of NF-□B and Egr-1 in flow-dependent restenosis after angioplasty and stenting. *Atherosclerosis*, **2011**, 214, 65-72	3.1	4
27	Catalytic oligonucleotides targeting EGR-1 as potential inhibitors of in-stent restenosis. *Annals of the New York Academy of Sciences*, **2001**, 947, 412-5	6.5	4
26	Left main coronary artery stenosis after percutaneous transluminal coronary angioplasty: importance of remaining "minimally invasive". *Catheterization and Cardiovascular Interventions*, **1999**, 46, 254-5	2.7	4
25	Early Growth Response-1, an Integrative Sensor in Cardiovascular and Inflammatory Disease. *Journal of the American Heart Association*, **2021**, 10, e023539	6	4
24	Coating Stents With Antirestenotic Drugs: The Blunderbuss or the Magic Bullet?. *Circulation*, **2002**, 105,	16.7	3
23	Novel negative regulatory element in the platelet-derived growth factor B chain promoter that mediates ERK-dependent transcriptional repression. *Journal of Biological Chemistry*, **2000**, 275, 11478-83	5.4	3

22	Therapeutic perspectives on pancreatic cancer. *Current Cancer Drug Targets*, **2013**, 13, 400-10	2.8	3
21	Discovery of widespread transcription initiation at microsatellites predictable by sequence-based deep neural network. *Nature Communications*, **2021**, 12, 3297	17.4	3
20	Coating stents with antirestenotic drugs: the blunderbuss or the magic bullet?. *Circulation*, **2002**, 105, E29	16.7	3
19	The streptozotocin-treated Sprague-Dawley rat: a useful model for the assessment of acute and chronic effects of myocardial ischaemia reperfusion injury in experimental diabetes. *Diabetes and Vascular Disease Research*, **2007**, 4, 153-4	3.3	2
18	Low flow promotes instent intimal hyperplasia. Comparison with lumen loss in balloon-injured and uninjured vessels and the effects of the antioxidant pyrrolidine dithiocarbamate. *Atherosclerosis*, **2004**, 177, 269-74	3.1	2
17	Deoxyribozymes as inhibitors of vascular smooth muscle cell growth. *Current Pharmaceutical Biotechnology*, **2004**, 5, 337-9	2.6	2
16	Repurposing Drugs for Skin Cancer. *Current Medicinal Chemistry*, **2020**, 27, 7214-7221	4.3	2
15	Serine 26 in Early Growth Response-1 Is Critical for Endothelial Proliferation, Migration, and Network Formation. *Journal of the American Heart Association*, **2021**, 10, e020521	6	2
14	Oxidative Stress and Endothelial Dysfunction. *Endothelium: Journal of Endothelial Cell Research*, **2004**, 11, 77-78		1
13	DNAzymes as molecular agents that manipulate Egr-1 gene expression. *Biochemical Pharmacology*, **2004**, 68, 1023-5	6	1
12	Novel and emerging therapies in cardiology and haematology. *Current Drug Targets Cardiovascular & Haematological Disorders*, **2003**, 3, 101-23		1
11	BT2 Suppresses Human Monocytic-Endothelial Cell Adhesion, Bone Erosion and Inflammation. *Journal of Inflammation Research*, **2021**, 14, 1019-1028	4.8	1
10	Truncated YY1 interacts with BASP1 through a 339KLK341 motif in YY1 and suppresses vascular smooth muscle cell growth and intimal hyperplasia after vascular injury. *Cardiovascular Research*, **2021**, 117, 2395-2406	9.9	1
9	The Yin and Yang of YY1 in tumor growth and suppression		1
8	Emerging insights on functions of the anthelmintic flubendazole as a repurposed anticancer agent. *Cancer Letters*, **2021**, 522, 57-62	9.9	0
7	Related transcriptional enhancer factor-1 induces fibroblast growth factor receptor-1 expression in endothelial cells. *Biochemical and Biophysical Research Communications*, **2009**, 380, 689-94	3.4	
6	Early Growth Response-1 Coupling in Vascular Endothelium818-821		
5	Immediate-early genes as master switches in disease. *Cell Biology International*, **2008**, 32, S3-S3	4.5	

4 The Endothelium and Cardiovascular Disease: New Developments, New Challenges. *Endothelium: Journal of Endothelial Cell Research*, **2006**, 13, 365-365

3 RNA sequencing identifies genes reliant upon Ser26 in early growth response-1 in vascular endothelial cells exposed to fibroblast growth factor-2.. *Vascular Pharmacology*, **2022**, 106952 5-9

2 Mechanisms of angiotensin II-induced platelet-derived growth factor gene expression **2000**, 183-186

1 Insights into Roles of Immediate-Early Genes in Angiogenesis **2013**, 145-162